AstraZeneca AZN announced that the European Commission has approved its blockbuster cancer drug, Imfinzi (durvalumab), for a ...

The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

British drugmaker AstraZeneca (LSE: AZN) has gained European approval for Imfinzi (durvalumab) in combination with ...

Drugmaker AstraZeneca said on Friday that its Imfinzi asset has been approved in the EU as the first and only perioperative ...

OPEN The FTSE 100 was expected to open 19.9 points lower on Friday after wrapping up the previous session 0.55% higher at 8,823.20.

AstraZeneca Pharma India shares saw a rise after Imfinzi got approval for expanded use. The CDSCO approved it as a first-line ...

The Cambridge, England-based pharmaceutical company said Imfinzi has been approved in the EU for treatments in adults with resectable muscle-invasive bladder cancer.

Imfinzi for stage III NSCLC that cannot be removed by surgery (PACIFIC study). On average, people who were treated with Imfinzi lived 16.8 months before their cancer got worse.

IMFINZI with IMJUDO and Platinum-Based Chemotherapy. Infusion-related reactions occurred in 2.9% (17/596) of patients receiving IMFINZI in combination with IMJUDO and platinum-based chemotherapy, ...

Imfinzi and Keytruda are both prescription drugs that treat certain types of cancer. Learn how their uses, effectiveness, and side effects compare.

Imfinzi and Tecentriq are both drugs used to treat certain cancers. Learn how they’re similar and different to help you decide if one may be right for you.